BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017;18. [PMID: 28335509 DOI: 10.3390/ijms18030667] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Mortoglou M, Tabin ZK, Arisan ED, Kocher HM, Uysal-Onganer P. Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy. Transl Oncol 2021;14:101090. [PMID: 33831655 DOI: 10.1016/j.tranon.2021.101090] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ge L, Pan B, Song F, Ma J, Zeraatkar D, Zhou J, Tian J. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open 2017;7:e018175. [PMID: 29282264 DOI: 10.1136/bmjopen-2017-018175] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
3 Łukaszewicz-Zając M, Gryko M, Pączek S, Szmitkowski M, Kędra B, Mroczko B. Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC). Oncotarget 2019;10:395-403. [PMID: 30719232 DOI: 10.18632/oncotarget.26571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ilies M, Sappa PK, Iuga CA, Loghin F, Gesell Salazar M, Weiss FU, Beyer G, Lerch MM, Völker U, Mayerle J, Hammer E. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer. Clinica Chimica Acta 2018;477:127-34. [DOI: 10.1016/j.cca.2017.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Litman-Zawadzka A, Łukaszewicz-Zając M, Gryko M, Kulczyńska-Przybik A, Kędra B, Mroczko B. Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer. Int J Mol Sci 2020;21:E6193. [PMID: 32867211 DOI: 10.3390/ijms21176193] [Reference Citation Analysis]
6 Li S, Zhang G, Li X, Li X, Chen X, Xu Y, Ren H. Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer. Pharmacogenomics 2021;22:657-67. [PMID: 34120460 DOI: 10.2217/pgs-2020-0183] [Reference Citation Analysis]
7 Li F, Liang J, Bai L. MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression. Biomedicine & Pharmacotherapy 2018;103:782-9. [DOI: 10.1016/j.biopha.2018.04.101] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
8 Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, Rachagani S, Natarajan G, Brand RE, Macha MA, Grandgenett PM, Kaur S, Batra SK. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. EBioMedicine. 2019;42:375-385. [PMID: 30956167 DOI: 10.1016/j.ebiom.2019.03.056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
9 Garces-Descovich A, Morrison TC, Beker K, Jaramillo-Cardoso A, Moser AJ, Mortele KJ. DWI of Pancreatic Ductal Adenocarcinoma: A Pilot Study to Estimate the Correlation With Metastatic Disease Potential and Overall Survival. AJR Am J Roentgenol 2019;212:323-31. [PMID: 30667305 DOI: 10.2214/AJR.18.20017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Zhou S, Yan Y, Chen X, Zeng S, Wei J, Wang X, Gong Z, Xu Z. A two-gene-based prognostic signature for pancreatic cancer. Aging (Albany NY) 2020;12:18322-42. [PMID: 32966237 DOI: 10.18632/aging.103698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Jugniot N, Bam R, Meuillet EJ, Unger EC, Paulmurugan R. Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer. Bioeng Transl Med 2021;6:e10183. [PMID: 33532585 DOI: 10.1002/btm2.10183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Manoochehri M, Wu Y, Giese NA, Strobel O, Kutschmann S, Haller F, Hoheisel JD, Moskalev EA, Hackert T, Bauer AS. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis. Mol Oncol 2020;14:1252-67. [PMID: 32243066 DOI: 10.1002/1878-0261.12684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S, Murrone A, Bianchi F, Amantini C, Giulietti M, Ricci G, Principato G, Santoni G, Berardi R, Cascinu S. Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS One 2019;14:e0215990. [PMID: 31048929 DOI: 10.1371/journal.pone.0215990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
14 Finnberg NK, Gokare P, Lev A, Grivennikov SI, MacFarlane AW 4th, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget. 2017;8:66747-66757. [PMID: 28977993 DOI: 10.18632/oncotarget.19965] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
15 Liu B, Yang H, Taher L, Denz A, Grützmann R, Pilarsky C, Weber GF. Identification of Prognostic Biomarkers by Combined mRNA and miRNA Expression Microarray Analysis in Pancreatic Cancer. Transl Oncol 2018;11:700-14. [PMID: 29631214 DOI: 10.1016/j.tranon.2018.03.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
16 Carmicheal J, Hayashi C, Huang X, Liu L, Lu Y, Krasnoslobodtsev A, Lushnikov A, Kshirsagar PG, Patel A, Jain M, Lyubchenko YL, Lu Y, Batra SK, Kaur S. Label-free characterization of exosome via surface enhanced Raman spectroscopy for the early detection of pancreatic cancer. Nanomedicine 2019;16:88-96. [PMID: 30550805 DOI: 10.1016/j.nano.2018.11.008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
17 Benzel J, Fendrich V. Familial Pancreatic Cancer. Oncol Res Treat. 2018;41:611-618. [PMID: 30269130 DOI: 10.1159/000493473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
18 Mattevi C, Garnier J, Marchese U, Ewald J, Gilabert M, Poizat F, Piana G, Delpero JR, Turrini O. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? BMC Surg 2020;20:176. [PMID: 32758203 DOI: 10.1186/s12893-020-00835-3] [Reference Citation Analysis]
19 Muñoz AR, Chakravarthy D, Gong J, Halff GA, Ghosh R, Kumar AP. Pancreatic cancer: Current status and Challenges. Curr Pharmacol Rep 2017;3:396-408. [PMID: 29404265 DOI: 10.1007/s40495-017-0112-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
20 Bararia A, Dey S, Gulati S, Ghatak S, Ghosh S, Banerjee S, Sikdar N. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions. Hepatobiliary Pancreat Dis Int 2020;19:205-17. [PMID: 32312637 DOI: 10.1016/j.hbpd.2020.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ma J, Cui Y, Cao T, Xu H, Shi Y, Xia J, Tao Y, Wang ZP. PDS5B regulates cell proliferation and motility via upregulation of Ptch2 in pancreatic cancer cells. Cancer Lett 2019;460:65-74. [PMID: 31233836 DOI: 10.1016/j.canlet.2019.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Igbinigie E, Guo F, Jiang SW, Kelley C, Li J. Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. Clin Chim Acta. 2019;488:226-234. [PMID: 30452897 DOI: 10.1016/j.cca.2018.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
23 Healy GM, Redmond CE, Murphy S, Fleming H, Haughey A, Kavanagh R, Swan N, Conlon KC, Malone DE, Ryan ER. Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival? Abdom Radiol (NY) 2018;43:620-8. [PMID: 28695235 DOI: 10.1007/s00261-017-1254-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
24 Macarulla Mercadé T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial. Pancreas 2020;49:62-75. [PMID: 31856081 DOI: 10.1097/MPA.0000000000001455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Fernández Aceñero MJ, Martínez-Useros J, Díez-Valladares L, García-Botella S, Ortega Medina L, Pérez Aguirre E, de la Serna Esteban S, Latorre E, Neelsen L. Still a place for conventional histopathological analysis in the era of molecular medicine: predicting prognosis of resectable ductal pancreatic adenocarcinoma. Clin Transl Oncol 2019;21:954-9. [PMID: 30565082 DOI: 10.1007/s12094-018-02008-4] [Reference Citation Analysis]
26 Cakmak G, Mantoglu B. Reliability and Quality of YouTube Contents Pertaining to Pancreatic Cancer. Cureus 2021;13:e14085. [PMID: 33907636 DOI: 10.7759/cureus.14085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yang X, Song S. Silencing of Astrocyte elevated gene-1 (AEG-1) inhibits proliferation, migration, and invasiveness, and promotes apoptosis in pancreatic cancer cells. Biochem Cell Biol 2019;97:165-75. [PMID: 30359541 DOI: 10.1139/bcb-2018-0181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Wei L, Yao K, Gan S, Suo Z. Clinical utilization of serum- or plasma-based miRNAs as early detection biomarkers for pancreatic cancer: A meta-analysis up to now. Medicine (Baltimore) 2018;97:e12132. [PMID: 30170450 DOI: 10.1097/MD.0000000000012132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
29 Dong D, Mu Z, Wang W, Xin N, Song X, Shao Y, Zhao C. Prognostic value of long noncoding RNA ZFAS1 in various carcinomas: a meta-analysis. Oncotarget 2017;8:84497-505. [PMID: 29137442 DOI: 10.18632/oncotarget.21100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Bagias G, Kanavidis P, Vailas M, Despotidis M, Sotiropoulou M, Katsaros I, Maroulis I, Filippou D, Schizas D. Surgical management of familial pancreatic cancer: a systematic review of the literature. ANZ J Surg 2022. [PMID: 35758214 DOI: 10.1111/ans.17834] [Reference Citation Analysis]
31 Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao L, Pei H. miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomed Pharmacother 2017;96:1341-8. [PMID: 29196101 DOI: 10.1016/j.biopha.2017.11.074] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
32 Hong L, Xu L, Jin L, Xu K, Tang W, Zhu Y, Qiu X, Wang J. Exosomal circular RNA hsa_circ_0006220, and hsa_circ_0001666 as biomarkers in the diagnosis of pancreatic cancer. J Clin Lab Anal 2022;:e24447. [PMID: 35446993 DOI: 10.1002/jcla.24447] [Reference Citation Analysis]
33 Gomez-Cambronero J, Fite K, Miller TE. How miRs and mRNA deadenylases could post-transcriptionally regulate expression of tumor-promoting protein PLD. Adv Biol Regul 2018;68:107-19. [PMID: 28964725 DOI: 10.1016/j.jbior.2017.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
34 Loosen SH, Luedde M, Lurje G, Spehlmann M, Paffenholz P, Ulmer TF, Tacke F, Vucur M, Trautwein C, Neumann UP, Luedde T, Roderburg C. Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer. Dis Markers. 2019;2019:5603474. [PMID: 31772690 DOI: 10.1155/2019/5603474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
35 Dhayat SA, Traeger MM, Rehkaemper J, Stroese AJ, Steinestel K, Wardelmann E, Kabar I, Senninger N. Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2018;10:E328. [PMID: 30217058 DOI: 10.3390/cancers10090328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
36 Zhou Z, Cheng Y, Jiang Y, Liu S, Zhang M, Liu J, Zhao Q. Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. Int J Biol Sci. 2018;14:124-136. [PMID: 29483831 DOI: 10.7150/ijbs.22619] [Cited by in Crossref: 52] [Cited by in F6Publishing: 71] [Article Influence: 13.0] [Reference Citation Analysis]
37 Barbosa IR, Santos CAD, Souza DLB. PANCREATIC CANCER IN BRAZIL: MORTALITY TRENDS AND PROJECTIONS UNTIL 2029. Arq Gastroenterol 2018;55:230-6. [PMID: 30540083 DOI: 10.1590/S0004-2803.201800000-59] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
38 Michael Traeger M, Rehkaemper J, Ullerich H, Steinestel K, Wardelmann E, Senninger N, Abdallah Dhayat S. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol 2018;144:2419-31. [DOI: 10.1007/s00432-018-2755-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
39 Liu J, Yu L, Ding W. Efficacy and safety of Kanglaite injection combined with radiochemotherapy in the treatment of advanced pancreatic cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019;98:e16656. [PMID: 31393364 DOI: 10.1097/MD.0000000000016656] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
40 Mortoglou M, Buha Djordjevic A, Djordjevic V, Collins H, York L, Mani K, Valle E, Wallace D, Uysal-Onganer P. Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma. Arch Toxicol 2021. [PMID: 34905088 DOI: 10.1007/s00204-021-03196-9] [Reference Citation Analysis]
41 Kong L, Liu P, Fei X, Wu T, Wang Z, Zhang B, Li J, Tan X. A Prognostic Prediction Model Developed Based on Four CpG Sites and Weighted Correlation Network Analysis Identified DNAJB1 as a Novel Biomarker for Pancreatic Cancer. Front Oncol 2020;10:1716. [PMID: 32984053 DOI: 10.3389/fonc.2020.01716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
42 Yan Q, Hu D, Li M, Chen Y, Wu X, Ye Q, Wang Z, He L, Zhu J. The Serum MicroRNA Signatures for Pancreatic Cancer Detection and Operability Evaluation. Front Bioeng Biotechnol. 2020;8:379. [PMID: 32411694 DOI: 10.3389/fbioe.2020.00379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Dackson Gudagunti F, Velmanickam L, Nawarathna D, Lima I. Label-Free Biosensing Method for the Detection of a Pancreatic Cancer Biomarker Based on Dielectrophoresis Spectroscopy. Chemosensors 2018;6:33. [DOI: 10.3390/chemosensors6030033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
44 Kamel F, Eltarhoni K, Nisar P, Soloviev M. Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection. Cancers 2022;14:1889. [DOI: 10.3390/cancers14081889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Yuan Q, Zhang Y, Li J, Cao G, Yang W. High expression of microRNA-4295 contributes to cell proliferation and invasion of pancreatic ductal adenocarcinoma by the down-regulation of Glypican-5. Biochem Biophys Res Commun 2018;497:73-9. [PMID: 29407175 DOI: 10.1016/j.bbrc.2018.02.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
46 Guerrero PE, Duran A, Ortiz MR, Castro E, Garcia-Velasco A, Llop E, Peracaula R. Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLex) in pancreatic adenocarcinoma. J Proteomics 2021;231:104004. [PMID: 33038510 DOI: 10.1016/j.jprot.2020.104004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Lu S, Ahmed T, Du P, Wang Y. Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. Int J Mol Sci 2017;18:E1201. [PMID: 28587243 DOI: 10.3390/ijms18061201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Putnin T, Ngamaroonchote A, Wiriyakun N, Ounnunkad K, Laocharoensuk R. Dually functional polyethylenimine-coated gold nanoparticles: a versatile material for electrode modification and highly sensitive simultaneous determination of four tumor markers. Mikrochim Acta 2019;186:305. [PMID: 31030268 DOI: 10.1007/s00604-019-3370-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
49 Winter K, Dzieniecka M, Strzelczyk J, Wągrowska-Danilewicz M, Danilewicz M, Zatorski H, Małecka-Wojciesko E. Hedgehog Signaling Pathway Proteins in Prognosis of Pancreatic Ductal Adenocarcinoma and Its Differentiation From Chronic Pancreatitis. Pancreas 2022;51:219-27. [PMID: 35584378 DOI: 10.1097/MPA.0000000000002001] [Reference Citation Analysis]
50 Xia LY, Tang YN, Zhang J, Dong TY, Zhou RX. Advances in the DNA Nanotechnology for the Cancer Biomarkers Analysis: Attributes and Applications. Semin Cancer Biol 2022:S1044-579X(21)00305-9. [PMID: 34979273 DOI: 10.1016/j.semcancer.2021.12.012] [Reference Citation Analysis]
51 Seufferlein T, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, Reni M, Falconi M, Philip PA, Van Cutsem E. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treat Rev. 2019;77:1-10. [PMID: 31163334 DOI: 10.1016/j.ctrv.2019.05.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
52 Ulutas KT, Sarici IS, Arpaci A. Comparison of Platelet Distribution Width and CA19-9 in Resectable Pancreas Cancer. Med Arch 2018;72:210-3. [PMID: 30061769 DOI: 10.5455/medarh.2018.72.210-213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
53 Li X, Li S, Liu L, Hong J, Zhao T, Gao C. Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma. J Cancer 2020;11:9-15. [PMID: 31892968 DOI: 10.7150/jca.33767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB; US Preventive Services Task Force. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2019;322:438-44. [PMID: 31386141 DOI: 10.1001/jama.2019.10232] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 34.3] [Reference Citation Analysis]
55 Llop E, Guerrero PE, Duran A, Barrabés S, Massaguer A, Ferri MJ, Albiol-Quer M, de Llorens R, Peracaula R. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. World J Gastroenterol 2018; 24(24): 2537-2554 [PMID: 29962812 DOI: 10.3748/wjg.v24.i24.2537] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
56 Ciernikova S, Novisedlakova M, Cholujova D, Stevurkova V, Mego M. The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma.Biomedicines. 2020;8. [PMID: 33287196 DOI: 10.3390/biomedicines8120565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
57 Mancera-Arteu M, Giménez E, Balmaña M, Barrabés S, Albiol-Quer M, Fort E, Peracaula R, Sanz-Nebot V. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma. J Proteomics 2019;195:76-87. [PMID: 30641231 DOI: 10.1016/j.jprot.2019.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
58 Li H, Zhou F, Cao Z, Tang Y, Huang Y, Li Y, Yi B, Yang J, Du P, Zhu D, Zhou J. Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:682969. [PMID: 34136406 DOI: 10.3389/fonc.2021.682969] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Townsend MH, Shrestha G, Robison RA, O'Neill KL. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res 2018;37:163. [PMID: 30031396 DOI: 10.1186/s13046-018-0817-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]